MedTrace Logo

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

NCT07154134 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-09-04

No results posted yet for this study

Summary

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Conditions

  • Endocan
  • Copeptin
  • Serum
  • Preterm Neonates
  • Respiratory Distress Syndrome

Interventions

DIAGNOSTIC_TEST

Serum endocan

Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

DIAGNOSTIC_TEST

Serum copeptin

Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Min Age
28 Weeks
Max Age
36 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154134 on ClinicalTrials.gov